Desq Long
Sign in

Company

REGENERON PHARMACEUTICALS, INC.

REGN · CIK 0000872589

SEC FORM 4
$41,941.35

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 55 shares at $762.57 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$19,094.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 25 shares at $763.76 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$167,403.60

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 219 shares at $764.4 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$207,420.69

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 271 shares at $765.39 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$213,845.13

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 279 shares at $766.47 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$147,338.88

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 192 shares at $767.39 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$80,674.65

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 105 shares at $768.33 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$97,701.10

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 127 shares at $769.3 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$9,242.40

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 12 shares at $770.2 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$218,351.48

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 283 shares at $771.56 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$163,010.16

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 211 shares at $772.56 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$173,241.60

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 224 shares at $773.4 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$93,712.08

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 121 shares at $774.48 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$291,572.96

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 376 shares at $775.46 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$51,236.46

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 66 shares at $776.31 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$29,554.88

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 38 shares at $777.76 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$353,502.56

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 454 shares at $778.64 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$296,244.20

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 380 shares at $779.59 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$361,431.69

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 463 shares at $780.63 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$39,073.50

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 50 shares at $781.47 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$4,522.56

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 6 shares at $753.76 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$26,456.85

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 35 shares at $755.91 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$12,122.88

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 16 shares at $757.68 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$18,195.84

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 24 shares at $758.16 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$10,639.44

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 14 shares at $759.96 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$56,288.10

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 74 shares at $760.65 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$20,556.72

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 27 shares at $761.36 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code S

Traded Oct 14, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$6,492,640.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Acquisition (code M) of 17,000 shares at $381.92 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code M

Traded Oct 13, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$9,698,616.74

REGENERON PHARMACEUTICALS, INC. (REGN)

Disposition (code F) of 12,853 shares at $754.58 per share.

Reporting Person MURPHY ANDREW J · Officer Title Co-Chief Scientific Officer · Transaction Code F

Traded Oct 13, 2026 · Disclosed Oct 15, 2026

Source: SEC Form 4 · 0001796226-26-000002 · filed 2026-10-15 · View filing →

SEC FORM 4
$969,708.09

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 1,131 shares at $857.39 per share.

Reporting Person McCourt Marion · Officer Title EVP Commercial · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001663758-26-000002 · filed 2026-09-03 · View filing →

SEC FORM 4
$1,032,750.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 1,215 shares at $850.0 per share.

Reporting Person McCourt Marion · Officer Title EVP Commercial · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001663758-26-000002 · filed 2026-09-03 · View filing →

SEC FORM 4
$287,748.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Acquisition (code M) of 400 shares at $719.37 per share.

Reporting Person Guarini Kathryn · Transaction Code M

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001992352-26-000007 · filed 2026-09-03 · View filing →

SEC FORM 4
$340,000.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 400 shares at $850.0 per share.

Reporting Person Guarini Kathryn · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001992352-26-000007 · filed 2026-09-03 · View filing →

SEC FORM 4
$4,690,741.44

REGENERON PHARMACEUTICALS, INC. (REGN)

Acquisition (code M) of 12,282 shares at $381.92 per share.

Reporting Person LAROSA JOSEPH J · Officer Title EVP General Counsel and Secret · Transaction Code M

Traded Aug 19, 2026 · Disclosed Aug 21, 2026

Source: SEC Form 4 · 0001238303-26-000002 · filed 2026-08-21 · View filing →

SEC FORM 4
$7,487,122.85

REGENERON PHARMACEUTICALS, INC. (REGN)

Disposition (code F) of 9,019 shares at $830.15 per share.

Reporting Person LAROSA JOSEPH J · Officer Title EVP General Counsel and Secret · Transaction Code F

Traded Aug 19, 2026 · Disclosed Aug 21, 2026

Source: SEC Form 4 · 0001238303-26-000002 · filed 2026-08-21 · View filing →

SEC FORM 4
$2,399,603.36

REGENERON PHARMACEUTICALS, INC. (REGN)

Acquisition (code M) of 6,283 shares at $381.92 per share.

Reporting Person Fenimore Christopher R. · Officer Title EVP Finance CFO · Transaction Code M

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0001697422-26-000002 · filed 2026-08-20 · View filing →

SEC FORM 4
$3,741,148.53

REGENERON PHARMACEUTICALS, INC. (REGN)

Disposition (code F) of 4,599 shares at $813.47 per share.

Reporting Person Fenimore Christopher R. · Officer Title EVP Finance CFO · Transaction Code F

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0001697422-26-000002 · filed 2026-08-20 · View filing →

SEC FORM 4
$301,352.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Acquisition (code M) of 800 shares at $376.69 per share.

Reporting Person Zoghbi Huda Y · Transaction Code M

Traded Aug 10, 2026 · Disclosed Aug 12, 2026

Source: SEC Form 4 · 0001681643-26-000006 · filed 2026-08-12 · View filing →

SEC FORM 4
$640,000.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 800 shares at $800.0 per share.

Reporting Person Zoghbi Huda Y · Transaction Code S

Traded Aug 10, 2026 · Disclosed Aug 12, 2026

Source: SEC Form 4 · 0001681643-26-000006 · filed 2026-08-12 · View filing →

SEC FORM 4
$287,748.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Acquisition (code M) of 400 shares at $719.37 per share.

Reporting Person Guarini Kathryn · Transaction Code M

Traded Aug 10, 2026 · Disclosed Aug 12, 2026

Source: SEC Form 4 · 0001992352-26-000005 · filed 2026-08-12 · View filing →

SEC FORM 4
$320,000.00

REGENERON PHARMACEUTICALS, INC. (REGN)

Sale of 400 shares at $800.0 per share.

Reporting Person Guarini Kathryn · Transaction Code S

Traded Aug 10, 2026 · Disclosed Aug 12, 2026

Source: SEC Form 4 · 0001992352-26-000005 · filed 2026-08-12 · View filing →

STOCK ACT PTR
$1,001 - $15,000

Regeneron Pharmaceuticals Inc (REGN)

Purchase.

Filer Ro Khanna · Chamber House · District CA17 · Transaction Type Purchase · Asset Type Stock

Traded Jul 7, 2026 · Disclosed Aug 7, 2026FILED +31 DAYS

Source: House Clerk PTR · 9116267 · filed 2026-08-07 · View filing →

STOCK ACT PTR
$1,001 - $15,000

Regeneron Pharmaceuticals Inc (REGN)

Purchase.

Filer Alan Armstrong · Chamber Senate · Owner Joint · Transaction Type Purchase · Asset Type Stock

Traded Mar 27, 2026 · Disclosed Jul 21, 2026FILED +116 DAYS

Source: Senate eFD PTR · fda235b3-bad7-4637-8fa1-053f354d929c · filed 2026-07-21 · View filing →

STOCK ACT PTR
$1,001 - $15,000

Regeneron Pharmaceuticals Inc (REGN)

Purchase.

Filer Alan Armstrong · Chamber Senate · Owner Joint · Transaction Type Purchase · Asset Type Stock

Traded Mar 27, 2026 · Disclosed Jul 21, 2026FILED +116 DAYS

Source: Senate eFD PTR · fda235b3-bad7-4637-8fa1-053f354d929c · filed 2026-07-21 · View filing →